According to PANews, Propanc Biopharma (NASDAQ: PPCB) has unveiled a new strategic initiative to acquire digital asset management (DAT) companies trading below their market-to-net asset value (MNAV).

Propanc Biopharma Plans Strategic Acquisition of Undervalued Digital Asset Firms

The company’s leadership believes the move could bolster Propanc’s balance sheet, diversify its asset base, and generate long-term value for shareholders. These DAT companies often hold substantial reserves of major cryptocurrencies such as Bitcoin (BTC) and Ethereum (ETH), providing a unique opportunity for exposure to the digital asset market.

Propanc’s board and executive team are currently developing a comprehensive due diligence framework to assess potential targets. This framework will evaluate factors such as balance sheet resilience, crypto asset holdings, and operational synergies between the firms.

The initiative highlights Propanc Biopharma’s growing interest in leveraging blockchain-driven value creation, marking a notable shift from its traditional biopharmaceutical focus toward digital finance and asset innovation.